Leerink Partnrs Weighs in on KalVista Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of KalVista Pharmaceuticals in a research report issued on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz expects that the specialty pharmaceutical company will post earnings of ($0.72) per share for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.70) EPS and FY2025 earnings at ($2.83) EPS.

A number of other research firms have also weighed in on KALV. Needham & Company LLC reiterated a “buy” rating and issued a $35.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, April 11th. HC Wainwright lifted their price objective on shares of KalVista Pharmaceuticals from $16.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV opened at $11.65 on Thursday. The firm’s fifty day moving average price is $12.85 and its 200 day moving average price is $11.24. KalVista Pharmaceuticals has a 1-year low of $7.21 and a 1-year high of $16.88. The firm has a market cap of $491.51 million, a price-to-earnings ratio of -3.70 and a beta of 0.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.09).

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KALV. JPMorgan Chase & Co. lifted its holdings in shares of KalVista Pharmaceuticals by 24.9% during the 1st quarter. JPMorgan Chase & Co. now owns 13,424 shares of the specialty pharmaceutical company’s stock worth $198,000 after acquiring an additional 2,677 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of KalVista Pharmaceuticals by 5.8% during the 1st quarter. Bank of New York Mellon Corp now owns 69,570 shares of the specialty pharmaceutical company’s stock worth $1,026,000 after acquiring an additional 3,838 shares during the period. MetLife Investment Management LLC raised its holdings in KalVista Pharmaceuticals by 103.8% in the first quarter. MetLife Investment Management LLC now owns 12,495 shares of the specialty pharmaceutical company’s stock valued at $184,000 after buying an additional 6,365 shares during the period. Rhumbline Advisers raised its holdings in KalVista Pharmaceuticals by 16.3% in the first quarter. Rhumbline Advisers now owns 22,150 shares of the specialty pharmaceutical company’s stock valued at $326,000 after buying an additional 3,100 shares during the period. Finally, BlackRock Inc. raised its holdings in KalVista Pharmaceuticals by 2.6% in the first quarter. BlackRock Inc. now owns 1,544,027 shares of the specialty pharmaceutical company’s stock valued at $22,757,000 after buying an additional 39,407 shares during the period.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par acquired 80,600 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were acquired at an average cost of $14.22 per share, for a total transaction of $1,146,132.00. Following the transaction, the insider now directly owns 4,650,584 shares of the company’s stock, valued at $66,131,304.48. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other KalVista Pharmaceuticals news, insider Edward P. Feener sold 28,288 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $14.07, for a total value of $398,012.16. Following the transaction, the insider now directly owns 62,157 shares in the company, valued at approximately $874,548.99. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Venrock Healthcare Capital Par bought 80,600 shares of KalVista Pharmaceuticals stock in a transaction on Monday, January 29th. The stock was purchased at an average price of $14.22 per share, for a total transaction of $1,146,132.00. Following the completion of the acquisition, the insider now owns 4,650,584 shares in the company, valued at approximately $66,131,304.48. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 207,227 shares of company stock worth $2,808,574 and have sold 75,978 shares worth $1,070,918. Insiders own 12.30% of the company’s stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.